-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Medical News, April 1st, in only one month, more than 30 pharmaceutical company executives resigned
Several well-known pharmaceutical company executives leave
In 2021, high-level personnel in pharmaceutical companies will continue to change frequently.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
On March 30, Xinlitai announced that it had recently received a written resignation report from independent director He Suying.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to Xinlitai's 2020 financial report, the company will achieve operating income of approximately 2.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
The reason for the shrinking performance is that Xinlitai’s "main product" clopidogrel bisulfate tablets (Jiatai) lost its standard in centralized procurement in 2019, and the main drug-eluting coronary stent in the medical device field also lost its standard.
Although the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
Although the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
On March 16, Beijing Tongrentang Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
It is understood that due to the severe impact of the epidemic, the business operation of Tongrentang in the first half of 2020 is not small, and its performance has declined.
However, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
However, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
Under the new situation, the development of Tongrentang is also faced with frequent drug quality problems and the problems of executives being investigated, which may directly cause the company's core executives to change.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
On March 2, Shanghai Fosun Pharma issued an announcement stating that the board of directors received a written resignation letter from the vice president Mr.
Chen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
Chen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
It is understood that Fosun Pharma has changed a lot of executives in recent years.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Fosun Pharma previously caused market controversy mainly because most of the company's profits came from investment income.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
In addition, multinational pharmaceutical companies such as Eli Lilly and Fresenius Group also have corresponding senior management changes in March under complex circumstances.
The following table is only an incomplete statistics of senior management departures since March.
The following table is only an incomplete statistics of senior management departures since March.
The market promotes transformation, and executives change frequently
From the perspective of position, deputy general managers and vice presidents are the positions that senior executives of domestic pharmaceutical companies resign intensively; from the perspective of the reasons for resignation, it is mainly due to "personal reasons", followed by "work reasons.
" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
With the continuous deepening of medical reform, the supervision of the medical industry has been continuously strengthened, and policies such as volume pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
In this complex background, on the one hand, the company needs new talents in the process of transformation.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
Although personnel changes in the pharmaceutical industry occur frequently, at the same time, it is also accelerating the flow of talents in the pharmaceutical market.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
Such a big environment will test the professional ability of "medical people".
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
Regarding this issue, Zhang Haoteng, head of the Nanjing Office of Houxin Investment, told the Securities Times that the pharmaceutical industry’s requirements for talents have two characteristics: one is that the threshold for professional quality is relatively high; the other is that the supervision of the pharmaceutical industry is relatively strict, so It also requires practitioners to have strong compliance capabilities.
"It requires both innovation and strict compliance.
"It requires both innovation and strict compliance.
In general, for corporate executives at home and abroad, it is necessary to accurately understand the pressure and opportunities brought about by the medical reform, follow the strategic adjustments of the company, and actively seek their own career choices.
Attachment: List of resignations of pharmaceutical company executives in March
Medical News, April 1st, in only one month, more than 30 pharmaceutical company executives resigned
Several well-known pharmaceutical company executives leave
In 2021, high-level personnel in pharmaceutical companies will continue to change frequently.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
On March 30, Xinlitai announced that it had recently received a written resignation report from independent director He Suying.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to Xinlitai's 2020 financial report, the company will achieve operating income of approximately 2.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
The reason for the shrinking performance is that Xinlitai’s "main product" clopidogrel bisulfate tablets (Jiatai) lost its standard in centralized procurement in 2019, and the main drug-eluting coronary stent in the medical device field also lost its standard.
Although the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
Although the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
On March 16, Beijing Tongrentang Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
It is understood that due to the severe impact of the epidemic, the business operation of Tongrentang in the first half of 2020 is not small, and its performance has declined.
However, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
However, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
Under the new situation, the development of Tongrentang is also faced with frequent drug quality problems and the problems of executives being investigated, which may directly cause the company's core executives to change.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
On March 2, Shanghai Fosun Pharma issued an announcement stating that the board of directors received a written resignation letter from the vice president Mr.
Chen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
Chen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
It is understood that Fosun Pharma has changed a lot of executives in recent years.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Fosun Pharma previously caused market controversy mainly because most of the company's profits came from investment income.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
In addition, multinational pharmaceutical companies such as Eli Lilly and Fresenius Group also have corresponding senior management changes in March under complex circumstances.
The following table is only an incomplete statistics of senior management departures since March.
The following table is only an incomplete statistics of senior management departures since March.
The market promotes transformation, and executives change frequently
From the perspective of position, deputy general managers and vice presidents are the positions that senior executives of domestic pharmaceutical companies resign intensively; from the perspective of the reasons for resignation, it is mainly due to "personal reasons", followed by "work reasons.
" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
With the continuous deepening of medical reform, the supervision of the medical industry has been continuously strengthened, and policies such as volume pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
In this complex background, on the one hand, the company needs new talents in the process of transformation.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
Although personnel changes in the pharmaceutical industry occur frequently, at the same time, it is also accelerating the flow of talents in the pharmaceutical market.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
Such a big environment will test the professional ability of "medical people".
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
Regarding this issue, Zhang Haoteng, head of the Nanjing Office of Houxin Investment, told the Securities Times that the pharmaceutical industry’s requirements for talents have two characteristics: one is that the threshold for professional quality is relatively high; the other is that the supervision of the pharmaceutical industry is relatively strict, so It also requires practitioners to have strong compliance capabilities.
"It requires both innovation and strict compliance.
"It requires both innovation and strict compliance.
In general, for corporate executives at home and abroad, it is necessary to accurately understand the pressure and opportunities brought about by the medical reform, follow the strategic adjustments of the company, and actively seek their own career choices.
Attachment: List of resignations of pharmaceutical company executives in March
Medical News, April 1st, in only one month, more than 30 pharmaceutical company executives resigned
Several well-known pharmaceutical company executives leave
Several well-known pharmaceutical company executives leave In 2021, high-level personnel in pharmaceutical companies will continue to change frequently.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
According to Cyberlan, in March alone, 35 pharmaceutical company executives announced their resignations, involving 31 pharmaceutical companies, and their positions include chairman, vice president, and chief executive officer.
For officials and others, “personal reasons” are the most common reason for resignation, followed by “job adjustment”.
There are 14 cases of positions above general manager, which is nearly double that of March last year.
On March 30, Xinlitai announced that it had recently received a written resignation report from independent director He Suying.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to relevant regulations, He Suying's term of office is about to expire, and he applied to resign from the position of independent director of Xinlitai.
At the same time, he resigned from the position of convener of the audit committee of the board of directors and member of the remuneration and assessment committee.
According to Xinlitai's 2020 financial report, the company will achieve operating income of approximately 2.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
739 billion yuan in 2020, a year-on-year decrease of 38.
74%.
This performance is not beyond the expectations of the industry.
Recalling the first quarterly, half-yearly, and third quarterly reports of Xinlitai in 2020, operating income has been declining during the reporting period.
The reason for the shrinking performance is that Xinlitai’s "main product" clopidogrel bisulfate tablets (Jiatai) lost its standard in centralized procurement in 2019, and the main drug-eluting coronary stent in the medical device field also lost its standard.
Although the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
Medical equipment medical equipment medical equipmentAlthough the proportion of revenue contributed by the medical device business is not large, the failure also means that the device field cannot relieve the revenue pressure of the main business.
On March 16, Beijing Tongrentang Co.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
, Ltd.
issued an announcement stating that the company’s board of directors received a written resignation from the company’s chairman Gao Zhenkun, and all directors unanimously recommended Di Shubing, secretary of the company’s party committee, director and general manager, to act as chairman of the board.
It is understood that due to the severe impact of the epidemic, the business operation of Tongrentang in the first half of 2020 is not small, and its performance has declined.
However, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
Medicine, medicine, medicineHowever, according to the company's 2020 annual report, Tongrentang technology subsidiary achieved operating income of 2.
367 billion yuan in the second half of 2020, a year-on-year increase of 18.
26% , The recovery is obvious, the production capacity problem is basically solved, and the core drugs maintain stable revenue.
Under the new situation, the development of Tongrentang is also faced with frequent drug quality problems and the problems of executives being investigated, which may directly cause the company's core executives to change.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
However, what kind of new development direction Tongrentang, which has been actively transforming and has finally achieved gains, will be expected after the new chairman takes office.
On March 2, Shanghai Fosun Pharma issued an announcement stating that the board of directors received a written resignation letter from the vice president Mr.
Chen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
Medicine Medicine MedicineChen Zhanyu.
Due to work arrangements, Mr.
Chen Zhanyu applied to the company's board of directors to resign from the position of vice president.
Mr.
Chen Zhanyu ceased to serve as the vice president of the company from March 1, 2021.
It is understood that Fosun Pharma has changed a lot of executives in recent years.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Last year alone, it issued announcements one after another, announcing that the company’s vice presidents Li Jianqing, Dai Kun, and Peng Yiran; senior vice presidents Hequn Yin; chairman Chen Qiyu; co-chairman Yao Fang, etc.
News of the executive's resignation.
Fosun Pharma previously caused market controversy mainly because most of the company's profits came from investment income.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
However, according to the company’s 2020 financial report, the revenue achieved in 2020 was 30.
307 billion yuan, an increase of 6.
02% year-on-year.
Among them, the pharmaceutical industry achieved revenue of 21.
880 billion yuan, accounting for 72.
19% of total revenue, mainly due to the past two years.
, Fosun Pharma has been approved for listing on multiple products and sold in large quantities, and innovative products have promoted sustainable growth in performance.
In addition, multinational pharmaceutical companies such as Eli Lilly and Fresenius Group also have corresponding senior management changes in March under complex circumstances.
The following table is only an incomplete statistics of senior management departures since March.
The following table is only an incomplete statistics of senior management departures since March.
The market promotes transformation, and executives change frequently
The market promotes transformation, and executives change frequently From the perspective of position, deputy general managers and vice presidents are the positions that senior executives of domestic pharmaceutical companies resign intensively; from the perspective of the reasons for resignation, it is mainly due to "personal reasons", followed by "work reasons.
" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
Enterprise business enterprise" In this regard, some analysts believe that whether it is for personal reasons or work reasons, the resignation of executives is related to the huge pressure currently facing the pharmaceutical industry.
With the continuous deepening of medical reform, the supervision of the medical industry has been continuously strengthened, and policies such as volume pharmnet.
com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
pharmnet. com.
cn/news/yyzb/" target="_blank">procurement have been promoted one after another.
The profit margins of some pharmaceutical companies have been squeezed, development strategies have also been affected, and innovation and transformation have to be accelerated.
In addition, the 2020 new crown epidemic has also affected the daily operations of many pharmaceutical companies, which in turn affected the company's revenue.
com.
cn/news/yyzb/" target="_blank">Procurementpharmnet.
com.
cn/news/yyzb/" target="_blank"> Procurement Procurement
In this complex background, on the one hand, the company needs new talents in the process of transformation.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
On the other hand, the abolition of executives is more efficient in terms of cost savings than the abolition of ordinary employees.
Therefore, the company’s executives are also facing certain pressures.
At present, most companies involved in volume procurement are chemical drug companies, and most of the pharmaceutical companies involved in this executive change are also chemical drug companies.
However, with the advancement of volume procurement, Chinese patent medicines and biosimilar drugs are bound to enter the market.
At that time, the executives of such pharmaceutical companies may usher in a round of changes.
Although personnel changes in the pharmaceutical industry occur frequently, at the same time, it is also accelerating the flow of talents in the pharmaceutical market.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
High-level talents have always been scarce, especially in this special period when companies are transforming.
It is expected that the battle for high-level talents in the pharmaceutical industry is about to start.
Such a big environment will test the professional ability of "medical people".
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
For those who are engaged in the pharmaceutical industry, they need to have a clear plan for their careers, clarify their choices and abilities, and know that their abilities can match their goals.
Which product line, which level, and whether there are any shortcomings, how should we strive to improve.
Regarding this issue, Zhang Haoteng, head of the Nanjing Office of Houxin Investment, told the Securities Times that the pharmaceutical industry’s requirements for talents have two characteristics: one is that the threshold for professional quality is relatively high; the other is that the supervision of the pharmaceutical industry is relatively strict, so It also requires practitioners to have strong compliance capabilities.
"It requires both innovation and strict compliance.
"It requires both innovation and strict compliance.
In general, for corporate executives at home and abroad, it is necessary to accurately understand the pressure and opportunities brought about by the medical reform, follow the strategic adjustments of the company, and actively seek their own career choices.
Attachment: List of resignations of pharmaceutical company executives in March
Attachment: List of resignations of pharmaceutical company executives in March 
